The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Dixon, Dave L.
Text and Data Mining valid from 2019-05-28
Version of Record valid from 2019-05-28
22 March 2019
10 May 2019
28 May 2019
Ethics approval and consent to participate
The authors declare that they have no competing interests.